Leerink says Jazz Pharmaceuticals (JAZZ -0.5%) shares don't reflect the positive aspects of the EUSA acquisition. In particular, Leerink says that the stock hasn't adequately priced in the true earnings potential from the deal. The firm sees opportunity for investors and reiterates an Outperform rating on shares with a $68 price target.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Wed, 4:20PM)
at Investor's Business Daily (Feb 26, 2015)
at Zacks.com (Feb 25, 2015)
at Benzinga.com (Feb 24, 2015)
at Investor's Business Daily (Feb 24, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs